BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessActinium Strengthens Executive Team and Enhances Clinical Development Capabilities with the Appointment of Dr. Mark Berger as Chief Medical OfficerBy Nasdaq OMXJan 18, 2017, 1:01 PM UTC
BusinessAffimed Provides Update on NK-Cell Immuno-Oncology PlatformBy Nasdaq OMXJan 11, 2017, 1:53 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 10, 2017, 12:00 PM UTC
BusinessKura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 and Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor ProgramBy Nasdaq OMXJan 4, 2017, 12:30 PM UTC
BusinessActinium Pharmaceuticals to Present at 9th Annual Biotech Showcase™ 2017 ConferenceBy Nasdaq OMXJan 4, 2017, 12:00 PM UTC
BusinessAmerican Health Council Names Robin Stewart, PhD, RN, OCN, CCRC to Nursing BoardBy Nasdaq OMXDec 29, 2016, 5:01 PM UTC
BusinessTesaro Announces Priority Review Designation for Niraparib NDABy Nasdaq OMXDec 20, 2016, 1:00 PM UTC
